Working… Menu

Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01842048
Recruitment Status : Unknown
Verified October 2016 by Shin Kong Wu Ho-Su Memorial Hospital.
Recruitment status was:  Recruiting
First Posted : April 29, 2013
Last Update Posted : October 13, 2016
Information provided by (Responsible Party):
Shin Kong Wu Ho-Su Memorial Hospital

Brief Summary:
The main goals of deep hyperthermia combined with external beam radiation (EBRT) on bone metastases are the response on pain relief, duration of response and time to achieve complete pain relief.

Condition or disease Intervention/treatment Phase
All Type of Cancers With Bony Metastasis Other: Hyperthermia Radiation: External-beam radiotherapy Phase 3

Detailed Description:

The goal of this study is to conduct comparative data on the efficacy of low temperature (40-43℃ range) deep hyperthermia adding on external beam radiation for treatment of metastatic bone tumors. There are 3 reasons of conducting this clinical trial. Firstly, radiotherapy is most effective modality for bony metastases treatment, but only limited radiation dose can be delivered to metastatic bony metastatic sites with relatively short response duration observed clinically. Since it is a palliative treatment for pain relief, some patients develop recurrent pain at the same lesions a few months later. Most patients must accept their hopeless conditions and accept toward the end of their lives due to difficulty of reirradiation. There is urgently need for more effective treatment. Secondly, most combination of hyperthermia and radiation trials were relatively high dose of radiation, with the basic idea of hyperthermic radiosensitization, the combination of hyperthermia and radiotherapy on bone metastasis is warrant. Clinical trials experiences on relatively less deep tumors such as breast, head and neck cancers, extremity sarcoma or melanoma may not be applied on deep seated tumors. Bony metastases are usually deep seated lesions with hard cortex bone surrounded. The real benefit of hyperthermia can be highlighted on bony metastases. Thirdly, metastatic bony microenvironment are critical for the providing of bone marrow-derived immune suppressor cells circulating to systemic tumor microenvironment, mild thermal therapy to metastatic bony microenvironment may have dual immunomodulatory effects: direct enhancement of immune cell activity through thermally sensitive molecular pathways associated with immune cell function/activation, and, indirect enhancement of immunosurveillance through a reduction in hypoxia-induced immune suppressor cells around metastatic foci via improved tumor vascular perfusion. An unexpected survival benefit may demonstrated from this study.

Patients are stratified according to solitary or multiple sites, primary cancer type (Breast or prostate vs others), and severity of pain (i.e., worst pain score in the last 24-hour period) (4-6 vs 7-10). Patients are randomized to 1 of 2 treatment arms.

Treatment protocol A was designed to compare the response of matched tumors in the same patient treated by radiation alone or by radiation combined with hyperthermia when the patient had multiple tumors. Two tumors of comparable size were treated with either protocol A or B, and the responses were compared. The tumor size was computed as the product of maximum length times maximum width.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Study Start Date : July 2013
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever

Arm Intervention/treatment
Experimental: External-beam radiotherapy combine hyperthermia
Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
Other: Hyperthermia
Radiation: External-beam radiotherapy
Active Comparator: External-beam radiotherapy alone
External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
Radiation: External-beam radiotherapy

Primary Outcome Measures :
  1. Complete response rate [ Time Frame: 24 weeks ]
    Complete response rate defined with Brief Pain Inventory score of zero plus no concomitant increase analgesic intake within 3 months after radiotherapy.

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 24 weeks ]
    Incidence of treatment-related adverse events from hyperthermia and RT.

  2. Tumor response [ Time Frame: 12 weeks ]
    To determine the difference of radiological tumor response in measurable indicated lesions on week 12.

  3. Pain relief [ Time Frame: 24 weeks ]
    To determine the difference in response of pain relief by Brief Pain Inventory score. To determine time and duration to pain relief on indicated lesion.

  4. Quality-of-life [ Time Frame: 24 weeks ]
    To compare the impact on quality-of-life using EORTC-C30 questionares.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or clinically confirmed solid tumor metastasis with index lesion involving or abutting bone. *Index lesion means an irradiated field covered lesions contoured from CT-Simulation which may generally less than 20cm, include 4-5 vertebra bodies, sacrum plus adjacent iliac lesions or a segment of femerol bone. Each patient can only have one index lesion for this study.
  • Index lesion with bone destruction either osteolytic or osteoblastic in nature as assessed on CT or MRI imaging
  • If the nature of the metastatic disease has been previously documented, the index lesion to be treated does not require further documentation (i.e., biopsy)
  • ≥ One primary painful metastatic site. The most painful site that need treatment first will be elected as index lesion site for evaluation of response. Additional less painful metastatic sites may be present. Patients who elect to have another course of RT treatment on different metastatic sites after the initial treatment are allowed.
  • Worst pain in the last 24 hours must be ≥ 4 on a 0-10 numeric scale.
  • Index lesion causing clinical or radiographic evidence of partial spinal cord or cauda equina compression/effacement is allowed.
  • Have developed pain or have persistent pain while on a stable chemotherapy, hormonal therapy, target therapy or bisphosphonate therapy regimen is allowed. There will be no change of chemotherapy, hormonal therapy, or bisphosphonate therapy for 4 weeks before and after radiotherapy
  • ECOG performance status 0-3
  • Life expectancy ≥ 3 months
  • Patients with impending fracture of weight bearing bone or patients with symptoms of spinal cord compression should have surgical opinion before the start of radiotherapy. Patient should not be able to be enrolled in this study if surgery is scheduled.

Exclusion Criteria:

  • Index lesion involves the skull
  • Index lesion has evidence of a pathologic fracture, impending fracture need immediate surgery are not eligible. Those patients had received decompression surgery are not eligible.
  • Has undergone prior radiotherapy at the index lesion
  • Those who chemotherapy or systemic treatment will be changed during study period.
  • Patients had history of metal implant inside or outside irradiation field are not eligible .
  • Patients had history of pacemaker insertion due to arrhythmia are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01842048

Layout table for location contacts
Contact: Kwan-Hwa Chi, M.D. 886-2-28332211 ext 2273
Contact: Yu-Shan Wang, Ph.D 886-2-28332211 ext 2614

Layout table for location information
Shin Kong Wu Ho-Su Memorial Hospital Recruiting
Taipei, Taiwan, 11101
Contact: Su-Chen Huang, M.S.    886-2-28332211 ext 2612   
Principal Investigator: Kwan-Hwa Chi Chi, M.D.         
Sponsors and Collaborators
Shin Kong Wu Ho-Su Memorial Hospital
Layout table for additonal information
Responsible Party: Shin Kong Wu Ho-Su Memorial Hospital Identifier: NCT01842048    
Other Study ID Numbers: 20120305D
First Posted: April 29, 2013    Key Record Dates
Last Update Posted: October 13, 2016
Last Verified: October 2016
Keywords provided by Shin Kong Wu Ho-Su Memorial Hospital:
External-beam radiotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes